Osteoporosis Management in Male Patients with Hypopituitarism

Diagnostic Assessment

The Endocrine Society recommends measuring serum free or total testosterone levels as part of the investigatory work-up for osteoporosis in men with hypopituitarism 3
The International Osteoporosis Foundation suggests using a female reference database for the densitometric diagnosis of osteoporosis in men 4
The World Health Organization recommends assessing fracture risk using FRAX to guide treatment decisions 4

The American College of Rheumatology recommends oral bisphosphonates (alendronate or risedronate) as first-line treatment for men at high risk of fracture 1, 2
The National Osteoporosis Foundation suggests intravenous bisphosphonates (zoledronate) or denosumab as second-line treatment if oral bisphosphonates are not tolerated or contraindicated 1, 2
The Endocrine Society recommends considering sequential therapy starting with a bone-forming agent followed by an anti-resorptive agent for very high fracture risk 1, 2
Abaloparatide is supported by the strongest BMD data for men at very high risk of osteoporotic fracture, according to the American College of Rheumatology 1, 2
Teriparatide significantly improves BMD at the lumbar spine and femoral neck, as reported by the National Osteoporosis Foundation 5, 4

The Endocrine Society recommends considering testosterone replacement therapy in men with documented low levels of total or free serum testosterone 3, 1, 2
Testosterone therapy has shown significant increases in lumbar spine trabecular volumetric BMD, cortical volumetric BMD, and areal BMD at the lumbar spine and hip, according to the International Osteoporosis Foundation 3

The National Osteoporosis Foundation recommends ensuring adequate calcium intake (1,000-1,200 mg daily) and vitamin D supplementation (800-1,000 IU daily) 4
The American College of Sports Medicine recommends physical exercise including balance training, flexibility exercises, endurance exercise, and resistance training 1, 4
The Academy of Nutrition and Dietetics suggests a balanced diet rich in calcium and protein 1, 4
The American Heart Association advises smoking cessation and limiting alcohol consumption 4

The International Osteoporosis Foundation recommends using biochemical markers of bone turnover to assess adherence to anti-resorptive therapy 1, 4
The National Osteoporosis Foundation suggests measuring bone turnover markers at baseline and at 3 months to monitor treatment response 4
The Endocrine Society recommends monitoring for potential side effects of both anti-osteoporosis medications and hormone replacement therapy 4

Anti-osteoporosis medications should be prescribed regardless of whether testosterone therapy is instituted, as testosterone alone does not adequately reduce fracture risk, according to the Endocrine Society 3, 1
Poor adherence is a significant issue with oral bisphosphonates, with up to 64% of men being non-adherent by 12 months, as reported by the National Osteoporosis Foundation 4